Patent Grant
9446197
N/A
There is a growing number of drugs and vaccines for which the most effective, or most convenient method of administration is by intranasal delivery. This has led to the development of dosing devices for spray into the nose. These devices must deliver a precise dosage amount and it is important to deliver the dose in a way that the drug is absorbed in the nasal cavity and does not enter the back of the throat or the lungs.
Another issue that arises with intranasal drug delivery devices is the potential for abuse. Many drugs with a substantial potential for abuse are sprayed or snorted into the nose by drug abusers. One aspect of intranasal device design, therefore, is to prevent the re-use or re-tasking of a used drug intranasal device. A powder dispenser device described in U.S. Pat. No. 5,683,361 provides a chamber with a powdery drug in which the chamber has a penetrable membrane enclosing either end. To dispense the drug, a plunger and piston are pressed against the lower end of the drug chamber, forcing it against a penetrating device connected to the dispensing nozzle and thus breaking the upper membrane. As the piston is depressed further, the lower membrane is penetrated by a lower penetration device, thus allowing the pressurized air above the piston to enter the drug chamber and expel the drug through the nozzle. This device requires that the air above the piston must be sterilized as well as the drug containing chamber, thus requiring sterilization of the entire device and secondary packaging. Another single dose dispenser is described in U.S. Pat. No. 5,307,953. This device also includes a plunger and a sealed drug containing chamber. A stainless steel needle is provided that communicates with the outlet nozzle. As the plunger is pressed by a user, the drug chamber is forced against the needle, which penetrates a membrane that seals the drug chamber. As the piston is pressed further, the drug is forced through the needle and out the nozzle.
U.S. Pat. No. 5,944,222 describes a dosing device in which a piston forces a drug containing chamber against a needle for release through the nozzle. The described device also includes a material bridge between the piston and the casing. By examining this bridge, one can determine if the piston has been previously pressed into the cylinder. This makes a tamper-evident closure so that it is apparent when someone is attempting to re-use a spent device.
A similar device with a piston and penetrating needle is described in U.S. Pat. No. 6,708,846. This device can also be placed in a reusable activating unit. The unit includes a ram which is adjustable with threads on the ram and on a sleeve containing the ram. During use of this device, a dispensing device is placed in the actuating unit and the ram is threaded into the sleeve so that the head of the ram rests against the piston of the dispensing device. A release detent holds the ram in place and prevents unwanted penetration of the drug compartment. The ram is also pressed against a compressed spring. Pressing the release button releases the detent, allowing the ram to push the piston and discharge the drug. A knob is then turned to reset the actuating device so it can receive another dispensing device for reuse.
Another dispenser, described in U.S. Pat. No. 6,725,857 is designed to dispense multiple doses of a drug, and is also designed for one-handed operation. Multiple drug doses are contained in storage chambers on a blister strip in the form of a drum store so that the strip is contained in the body of the device and is moved along a wheel as each dose is dispensed. An actuating lever is pressed against a spring and when the spring is compressed, a lock holding a carrier plate is released. The compressed spring then drives the plate and attached slides that push the wheel so that the next dose chamber is aligned with the punch, the punch is moved down into the chamber, puncturing the enclosing film, and air pressure created within the body of the device expels the drug from the chamber. The user then returns the actuating lever to the original position and the process can be repeated for the next dose.
The present disclosure provides drug or pharmaceutical delivery devices, unit dosage forms containing medical compositions for use in the devices, and methods of delivering medical compositions to a user. As used herein, the term “unit dosage form” is intended to convey its art accepted meaning, and includes, but is not limited to ampul (ampoule), blister, cartridge, bottle, vial, unit-dose vial, or container, which terms are used interchangeably herein. In preferred embodiments, an unit dosage form contains a single-unit dose of a substance, or a two-unit dose of one substance or two different substances, in one or more compartments of the unit dosage form. Alternatively, an unit dosage form may administer three or more substances from one or more compartments in an unit dosage form. During manufacture, the unit dosage forms can be singulated, i.e., individually broken apart and individually loaded into, for example, an unit dosage form cartridge or a device. Alternatively, the unit dosage forms can be interconnected, for example through a strip, disk or connected webbing. The unit dosage forms can be manufactured as a disk or strip of unit dosage forms, which then may be manipulated into different forms for administration, such as a circle, ring, or tube. In other preferred embodiments, the unit dosage forms themselves, or the Unit dosage form Cartridge Holder, adhere to a numbering, color coding, icon system coding, or Braille system for assisting the user in administration of the unit dosage forms, and may also include a bar code or Radio Frequency Identification Device (RFID).
In certain embodiments the unit dosage forms of the present disclosure are blisters that can be manufactured as described in U.S. Provisional Ser. No. 60/972,634, incorporated in its entirety herein by reference. The manufacturing processes for shaping articles for unit-dose packaging with at least one formed recess (e.g., a blister), in particular for unit-dose packaging of pharmaceutical dosage forms, can include a step of drawing the film material (e.g., metal-plastic foil) with one or more plungers to form a primary contour, the contour having a depth of at least 100% and up to 150% of the depth of the formed recess. A second stage involves shaping the primary contour with one or more plunger(s) to the desired formed recess, with a depth that is less than the depth of the primary contour, while substantially maintaining the surface area of the primary contour formed in the first stage. The formed recess may be formed using warm-forming or cold-forming techniques.
The disclosed devices may be described in certain embodiments as devices for dispensing a predetermined quantity of fluid into the nasal passage of a user, or into the eye or ear of a user, in which the predetermined quantity of fluid is contained in, or produced in an ampul or blister dosage form that is crushed by a plunger with sufficient force to drive the dosage form against a piercing mechanism, piercing the dosage form and forcing the liquid contents from the dosage form and through a delivery channel into a spray to be directed to the user. A predetermined quantity refers, in most instances to a single dose of medication or a pharmaceutical or medical composition, and in certain embodiments to a prescribed dose. A predetermined quantity of fluid may also be a partial dose when delivery of a dose is administered in two or more spray events. Any pharmaceutical agent that is deliverable in a powder or liquid from is contemplated in the present disclosure, including but not limited to antibiotics, antipyretics, anti-inflammatories, biologics, vitamins, co-factors, enzymes, inhibitors, activators, nutrients, aptamers, thioaptamers, vaccines including killed or live virus or microorganisms, nucleic acids, proteins, peptides, antibodies, peptide mimetics, or other agents known in the art. The medical compositions are in the form of a liquid, a powder, or a combination of liquid and powder and include one or more active agents and combinations of pharmaceutically acceptable carriers, solvents, diluents, preservatives, surfactants, salts, adjuvants, viscosity agents, buffers, chelators, or other ingredients known to those in the art as needed.
Although preferred embodiments of the devices are described herein primarily for use as intranasal delivery devices, it is understood that in certain embodiments the described devices can also be used for delivery to the eye, ear, mouth, lungs, or topical cutaneous areas of a user, by modification of the nozzle end of the devices. The devices can also be produced for veterinary use, for delivery of drugs to the nose, eye or ear of an animal. For example, a device may include a nozzle for delivery into the ear canal of a user, or it may include a cup or nozzle for delivery to the eye of a user. The volume of a dose delivered for the various uses can also be adjusted as appropriate.
The volume of droplets or particles dispensed from the devices will depend on the site of dispensing as well as the content and viscosity of the medication to be delivered. In certain embodiments droplet to be delivered to the eye would be from 1 μl to 25 μl, or more typically from 7 μl to 25 μl. Dosage for nasal administration are typically from 75 μl to 500 μl and dosages for oral or topical cutaneous administration can be larger, as much as 1000 μl or more. The volume and size of droplets or particles released by a device can be adjusted to maximize the therapeutic benefit of the dispersed substance. The volume of substance dispensed depends on the size of the compartment containing the substance, the unit dosage form blister, the piercer, the fill level, the degree to which the dosage form is compressed by the device and other variables in the construction of the devices, as well as characteristics of the substance dispersed, which are well understood by those skilled in the art. These variables can be appropriately dimensioned to achieve dispersal of a desired volume or droplet size of liquid or particle size of substance to the user. One of skill in the art understands that residual liquid or other substance after dispersal is taken into account when formulating the appropriate parameters for dispersing the desired dosage volume.
An advantage of the devices and unit dosage form designs set forth herein is that the sterility of the administered substance is maintained until the moment of use. Maintaining sterility until the moment of use minimizes or eliminates the need to use preservatives or bacteriostatic compounds in the substances administered, without risking contamination. In addition, if the unit dosage form is damaged, or is otherwise defective, the devices do not administer the substance, which may no longer be sterile. For example, if an unit dosage form is defective in the area of the pierceable section, or develops a leak, the devices will not dispense the substance properly because sufficient pressure will not be generated in the unit dosage form to effectively release the substance.
The devices typically include a body with a nozzle end for insertion into the nostril of a user, a trigger device to be operated by a user, a dosage form, either an ampul or a blister, containing a composition to be delivered and including a piercable membrane, a cavity within the body or nozzle containing the dosage form, a plunger or piston body, an actuator mechanism linking the trigger device to the plunger, a piercing mechanism positioned to pierce the dosage form upon activation of the trigger, and a discharge channel to release a spray of the liquid composition through the nozzle in a predetermined spray plume geometry and direction.
The dosage forms of the disclosure are described, in certain embodiments as including a dispensing blister chamber that contain a piercing device, wherein the piercing device is a substantially hollow, elongate member with a base end and a piercing tip opposite the base end and providing a discharge nozzle. In certain embodiments the dispensing blister conforms to at least the base end of the piercing device effective to support and hold the piercing device in place during manufacture and use of the dosage form. The piercing devices include one or more inlet openings on or near the base end and an internal conduit providing fluid communication between the one or more inlet ports and the discharge nozzle; and the surface of the internal conduit comprises structural features such as contours, steps, flutes, ribs, constrictions, or a combination thereof to control the spray pattern and droplet size of a fluid forced through the piercing device. It is a further aspect of the disclosure that the inlet openings provide a fluid path from the interior of the dispensing blister chamber into the internal conduit that comprises one or more bends, and that the combination of angular turns and the structural features of the internal conduit create vortices in the fluid as it is forced through the piercing mechanism.
The structural features can be designed, for example, for different types of spiral, vertical and other flow and the design can be adjusted for different viscosities of the fluid or solid to be dispensed. For example, structural features may be added to create a vortex, to further mix the contents of the blister, to change the fluid property type from laminar to turbulent or vice versa or to change fluid properties such as pressure, velocity, surface tension or viscosity. Additionally, the inlets into the internal conduit can include bends of angles from about 0° to 90°, or more combinations in order to create the desired spray plume geometry for a particular medicament or liquid dose.
In certain embodiments, a shaped blister dosage form as described herein that contains medication and an internal piercing nozzle, is configured for use in a smaller diameter dispensing mechanism, while still providing an accurate dose of medicine in the form of a controlled spray. A blister strip including a plurality of such dosage forms can include a blister material layer in which the dosage forms are formed, and a lid material bonded to the blister material. A concentric sealing area provides a resilient seal that is not broken when the dosage forms are crushed to deliver the contained medication.
To produce a controlled spray of liquid when bursting a sealed formed recess, such as a shaped blister, an internal piercer inside the sealed blister may be used, and may be positioned such that it maintains contact with the lid material. Internal piercers are disclosed in U.S. Ser. No. 11/114,251, U.S. Prov. Nos. 60/853,328 and 60/944,379, each of which is incorporated herein by reference. The internal piercer can take different shapes, including but not limited to a funnel design, or a disc shape design. The internal piercer can constructed of materials any suitable materials such as ceramic, glass, metal, styrene, polystyrene, plastics, including but not limited to PET, polypropylene, polyethylene, or PEEK, and other pharmaceutical grade FDA approved materials of sufficient hardness to penetrate the lid material. The second, subsequent and/or final plunger(s) may be designed to shape the formed recess such that the internal piercer is locked into place within the formed recess, e.g., through manufacture, handling, transportation, storage, and actual use. For example, in a shaped blister, a protruding structure, an indentation, a diaphragm or an annulus is formed to conform to the shape of the base of the internal piercer. The protruding structure, indentation, diaphragm, or annulus provides support for and holds the internal piercer in place during assembly and during dispensing. Thus, these structures functions to capture the internal piercer (e.g., restrict vertical movement of the piercer), thereby holding it in place. The internal piercer may also be held in place through manufacture and actual use by, for example, press fit, welding, hydrostatic forces, or electrostatic forces. The shaped blister can also be formed by the second or subsequent plunger such that it insures that the protruding structure, indentation, diaphragm, or annulus seals to the internal piercer in order to achieve the desired spray pattern.
In preferred embodiments, the internal piercer includes a hollow tube or channel (the delivery channel) through which the pharmaceutical dosage form flows as the shaped recess is compressed and pierced. The tip of the piercer preferably has an angled edge to aid in penetration of the lid material. The inside diameter of the piercer tube can range from about 0.015 inches to about 0.05 inches, but in certain preferred embodiments is about 0.025 inches. The internal diameter, shape, or surface texture of the delivery channel, whether in, near, and/or at the exit point, may contain a nozzle or may be varied to form the optimum droplet size and spray plume geometry of the pharmaceutical dosage form as it exits the shaped article, as well as control the velocity, pressure, pattern, distribution, and aim of the released substance. Thus, the nozzle system and the piercer may be integrated into a single unit. The nozzle system can also be designed to determine the mixing of the substance as it is released.
To successfully dispense the medication, the medication must flow through the piercing nozzle with enough velocity to create the desired spray geometry. As described herein, this is accomplished by pressing on the blister form with sufficient force to push the piercing nozzle through the lid material, completely crushing the dosage form and forcing the contents through the nozzle with the required velocity. During this dispensing operation, the seal of the lid material to the blister material must be strong enough that no leakage occurs prior to the nozzle piercing the lid. The smaller size required by certain dosage situations, such as intranasal administration present greater challenges to the seal of the lid material to the blister material.
It is an aspect of the disclosure that the disclosed devices also include actuator mechanisms that provide a mechanical advantage, a mechanical disadvantage, or a combination thereof to the discharge process. Mechanical advantage, as used herein, indicates that the amount of force exerted on the plunger or piston to crush a dosage form and deliver the medication is greater than the amount of force applied by a user on the trigger device. Mechanical disadvantage, as used herein, indicates that the amount of force exerted on the plunger or piston is less than the amount of force applied by a user on the trigger device. In certain embodiments, the actuator mechanism provides a mechanical disadvantage during a first stage of the firing action and a mechanical advantage during a second stage of the firing action. In an example of such a system, an actuator can provide a mechanical disadvantage in a first stage of the firing process, forcing a user to exert an increased level of force to the trigger mechanism, during the firing process, the actuator can then shift to a mechanical advantage in which the increased force being exerted by the user is enhanced to provide sufficient force to correctly dispense the dosage. It is understood that the first and second stages, however, do not necessarily refer to the time position in the firing order, but could occur in reverse order. The devices are thus able to drive the plunger with sufficient force to crush the dosage form and deliver the composition in the dosage form through the nozzle with sufficient force to create the desired spray pattern and geometry.
In certain embodiments, the mechanical advantage is provided by a toggle mechanism. The toggles of the present disclosure include jointed rods or bars with several flex points so the toggle is joined to the trigger device by a flexible joint and joined to the piston device with a flexible joint. The toggle further includes a flex point at or near the center of the bar or rod. At the flex point, the two sections of the toggle form at an angle of about 90° or greater. It is understood that at 90°, the force at the apex and at the end of the linkage are in a 1:1 ratio, but as the angle increases, the force at the piston end becomes greater than the force at the apex. As such, the angle formed at the apex may any angle that is about 90° or more, including 90°, 95°, 100°, or even 135° to provide the required amount of mechanical advantage. The apex of this angle contacts the trigger device when the device is in the ready mode or position. When the trigger is then activated or pressed by a user in the direction of the angle bisector, as the toggle moves away from the direction of force and the plunger is pushed against the dosage form flattening the angle in the toggle toward 180°, then the force applied to the end of the toggle that is joined to the plunger is greater than the force applied at the apex of the angle.
Certain disclosed devices include an activation knob that is rotatable from an inactive to an active position. The activation knob is particularly suitable for use with a toggle mechanism for providing mechanical advantage. In the inactive or storage position the knob, the cross section of the knob conforms to the shape of the body of the device such that the long axis of the knob is aligned with the long axis of the body. The knob is joined to the toggle is such a way that the plane of the angle in the toggle is also aligned or parallel to the long axis of the body. Rotating the knob through 90° into the ready position, places the long axis of the knob perpendicular to the long axis of the body, and raises the angled toggle against the button or trigger device. This pushes the button up into the ready, or cocked position. In certain embodiments, the underside of the button provides a depression that complements the geometry of the toggle and prevents the toggle from slipping when the button is pushed.
The described devices include devices designed for a single use, or the devices are designed to be disposable after a single use. Certain devices are also reloadable or capable of holding and/or dispensing more than a single dose. The devices incorporate designs that prevent a reuse of or repurposing of the devices. The toggle can be made of an inexpensive material, therefore, such as a semi-rigid plastic or polymer material, or of any other semi-rigid material known in the art including metals such as aluminum, for example. The toggle mechanism can be made of a single piece of material in which the activation knob, actuator and plunger are all formed of a single piece, or the mechanism can be made of two or more pieces. The toggle can be made of two bars, joined at the center with a hinge pin, and joined at either or both ends with hinge pins or other flexible joints.
In certain embodiments the mechanical advantage of the actuator can be provided by a pivoting linkage. A device with a pivot mechanism can include a pivot arm and a grip arm designed so a user holds the device in one hand with the fingers on the pivot arm and the thumb on the grip arm. The device is fired by squeezing the fingers and thumb together to bring the pivot arm into contact with the grip arm, or the progress of the pivot arm toward the grip arm can be limited before it reaches the grip arm, by the length of the piston stroke. The pivot arm includes an attachment to the body at a pivot point and a projection that enters the body of the device, forming a pivot ram that contacts the plunger or piston body. The pivot ram is closer to the pivot point than to the opposite end of the pivot arm. This placement of the pivot ram provides the mechanical advantage to the pivot mechanism.
An aspect of the design of a pivot arm device is the placement of the device during use. In order to deliver the full dosage amount to a user when the device is for intranasal delivery, it is important that the pharmaceutical is delivered and absorbed to the nasal mucosa rather than entering the throat or lungs of the user. The pivot device is designed to provide the correct alignment. When the device is held in the hand of a user as described and the discharge nozzle is placed into a nostril of the user, placing the thumb in the depression in the chin under the lower lip provides for the correct alignment. This method of holding the device also provides stability so the device can be held steady when the user fires it.
In certain embodiments, the mechanical advantage can be provided by a lever mechanism. In preferred embodiments the lever mechanism includes a lever arm in which the linkage is connected to the lever arm by a slidable hinge and pin connection. In this embodiment, a pin near the end of the linkage member or actuator slides in a groove or slot in a hinge attached to the lever arm. In the storage position, the lever arm is folded against the body, and as the arm is raised to the ready position the linkage slides in the slot until the end of the mechanism comes to rest in a notch in the underside of the lever arm. Placement of the end of the linkage in the notch prevents the linkage from sliding back along the lever arm and provides a steady base from which to force the linkage against the plunger. The mechanical advantage is provided by the placement of the notch nearer the attachment point of the lever arm to the body than to the end of the lever arm. Certain devices can include an alignment device to correctly position the device for delivery to the nasal mucosa. A bite arm is extendable from the body, in a position such that when the discharge nozzle is placed in a nostril of a user and the bite arm is held in the teeth of the user, the device is positioned to control the direction of the discharge into the nasal passage of a user during use.
The mechanical advantage of the delivery devices disclosed herein can also be provided by one or more inclined planes. In these embodiments, typically a button projects from the rear of the device, or the side furthest from the discharge nozzle. The button is connected to an actuator that is an elongated member with a wedge-shaped projection toward the top of the device. This wedge shaped projection acts as an angled cam. The end of the linkage opposite the button is a ram for contacting and crushing a dosage form such as an ampul or blister. In such an embodiment, the angle of the camming surface or surfaces can be designed to provide a mechanical advantage, a mechanical disadvantage or a combination by a change in the slope or angle of the cam surface. The button, linkage or actuator and ram are rigidly connected and can be constructed of a single piece of a hard plastic or metal material. In this mechanism, the firing button, disposed on the top of the device also includes a projection, which may be an elongated member, a square or rectangular projection or an or angled cam or plane, projecting downward from its lower or inside surface. As the activation button is pushed in, the forward face on the linkage cam moves in a forward direction, contacting the projection on the cam on the firing button, thus raising the firing button into the ready position, and positioning the ram adjacent an ampul or blister. In the ready position, the firing button projection contacts the opposite face of the cam such that pushing the firing button down forces the linkage forward into the ampul, and providing a mechanical advantage relative to the force applied to the button. In certain embodiments the two faces of the actuator cam are formed by a single wedge-shaped structure, or they may be separate structures.
The disclosed devices can also provide a mechanical advantage or disadvantage to the firing process through the use of a spring or electro-mechanical mechanism. Examples of such mechanisms are described in commonly owned U.S. application Ser. No. 11/114,251, incorporated herein in its entirety by reference.
In certain embodiments, an inclined plane or angled cam mechanism is used in devices designed to deliver two or more sequential dosages. An example of such a device is an elongated tube-like device with a delivery nozzle at each end. The linkage is a sliding member with a ram at either end and one or more angled cam projections configured to interact with one or more angled cams projecting from a firing button. The sliding mechanism can be moved toward either end of the device to place the ram and button in ready position for firing a dose from the selected end. After a first dosage is dispensed, the sliding member can be moved to the opposite in ready position and then fired to dispense a second dose from that end.
It is a further aspect of the disclosure that the described devices can include a latch that locks the dispensing mechanism upon discharge, thus preventing re-use or re-purposing of the device. In certain embodiments a hook-shaped latch is forced into a similar opposite facing hook-shaped latch when the devices are fired, locking the pieces together and preventing reversal of the process to return the device to ready position. The latches may be on the actuators or on the pistons and mate with similar latches on the body of the devices. In certain embodiments, the linkage device is designed to break or separate when the plunger has reached its full stroke, thus disabling the device for further use. As a further safety feature, the devices can be designed such that the bodies cannot be opened without destroying the device to prevent re-use.
In certain embodiments the devices also include detent devices. A detent can be a projection, tab or flange on the plunger or piston, for example, that impinges on a groove or slot in the body. The detent is semi-rigid so that it resists a certain amount of force, and only flexes and thus releases the piston when a sufficient, predetermined force is applied. In this way, the devices ensure that sufficient force is applied to the piston to completely crush the dosage form and deliver the entire dose in the desired spray geometry.
The devices of the present disclosure can employ a piercing mechanism that is external to the dosage form, or they may employ dosage forms that contain an internal piercing mechanism. Preferred piercing mechanisms include a piercing point positioned adjacent the piercable membrane of the dosage form and a tube providing fluid communication from the piercing point to the discharge nozzle. In certain embodiments the piercing mechanism comprises a piercing body, wherein the outer dimensions of the piercing body closely fit in the inner dimensions of the dosage form such that when the piercing body pierces the dosage form and discharges the fluid during use, the piercing body displaces substantially the entire internal volume of the dosage form.
In certain embodiments the piercing mechanism is contained in the dosage form with the fluid to be delivered. Such internal piercing mechanisms can include an internal chamber, one or more inlet openings arranged to force one or more bends or changes in direction as the fluid flows into the internal chamber, a discharge outlet, and features on the internal surface to control the spray pattern and droplet size of a fluid forced to flow through the nozzle. The changes in direction can be of any appropriate angle, including from about 1° to about 90° or more. The design of such features are known to those of skill and include steps, flutes, ribs, or a combination thereof.
Certain embodiments of the delivery devices of the disclosure can be reusable. A reusable device can include a removable tip that contains one or more dosage forms and a piercing mechanism. The dosage form can be swaged into the removable tip thereby reducing the overall diameter of the dosage form while preserving the seal area of the dosage form. The piercing mechanism can be contained in an internally pierced dosage form as described herein. The removable tip is fit onto the body to place the dosage form adjacent the plunger, and can be connected to the body with a bayonet fitting, or other type of connection known to those of skill in the art.
The present devices can also be designed to provide the dosage in two separate discharges. Such devices can include a rotatable tip, for example that controls the amount to be discharged. The tip is designed so a shoulder in the interior of the tip is contacted by a tab on the plunger, stopping the plunger and thus the discharge when the dosage form is partially emptied. In certain embodiments the plunger stops when the dosage form is half empty. Rotating the tip, then, would rotate the shoulder away from the tab, aligning a channel or multiple channels with one or more tabs on the plunger. This second alignment would allow the rest of the dose to be dispensed when the trigger is again activated. In preferred embodiments the tip includes position indicators and the body includes an alignment mark. In this way, when a “1” on the tip is aligned with the alignment mark on the body, the device will dispense the first portion, and when a “2” is aligned with the alignment mark the device will dispense the remaining dose. Any numbers, letters, symbols, colors or other indicators can be used on the tip to indicate the position of the tip for dispensing drug. It is also understood that there can be a position marked “0” for example, in which the device is locked and cannot be used until the tip is rotated to the first active position. In this embodiment, a series of detent mechanisms may be used so that the detent is active for each portion of the dose.
In certain embodiments the disclosure may be described as a piercing nozzle for dispensing fluid from a dosage form in a controlled spray pattern and droplet size. The nozzle includes a substantially elongate member with an inlet end and a discharge end, an internal channel connecting the inlet end and the discharge end in fluid communication, one or more inlet openings in the inlet end, a discharge opening in the discharge end, and features on the internal chamber surface to control the spray pattern and droplet size of a fluid forced through the nozzle. The inlet ports are designed to provide a fluid path into the internal channel that includes one or more right angle turns. The inlet ports can also be designed to produce a vortex in the liquid as it is forced through the ports. Features in the internal channel can also include, but are not limited to steps, flutes, ribs, and related structures to produce the desired droplet size and spray geometry. In certain embodiments, the piercing tip may be on the discharge end of the elongated member, or on the inlet end. The piercing nozzle can be contained in a dosage form. The disclosure includes, therefore, a dosage form containing the piercing nozzle and a medical or pharmaceutical composition.
In certain embodiments the present disclosure can be described as an internally pierced dosage form that includes a substantially dome shaped, flexible blister, a substantially round pierceable surface sealed to the base of the dome-shaped blister, and an internal chamber containing a piercing nozzle as described herein and a liquid composition. In certain embodiments the piercing nozzle includes a base and a piercing end, and wherein the base is attached to the dome shaped blister and the piercing end is proximate the piercable surface.
Certain embodiments of the disclosure include dosage forms in which two or more components are mixed just prior to dispensing. Such a dosage form can include a blister and a backing, where the blister is divided into two or more chambers. The chambers are divided by seals that are less adhesive than the primary seal that surrounds the circumference of the total blister. In this embodiment, each chamber contains a powder or liquid portion of the final dose to be mixed, and at least one chamber contains a liquid such that the final mixture is in liquid form. It is an aspect of this embodiment that the contents of one chamber is forced into the interior of an adjacent chamber where the two components are mixed. This is accomplished by applying a force to the first chamber that is sufficient to break the less adhesive seal between chambers without breaking the primary circumferential seal around the blister, and crushing the first chamber to force the contents to enter the second chamber under pressure. The second chamber is preferably composed of a flexible blister material with the top inverted to minimize the volume of the second chamber prior to mixing. Breaking the seal and forcing the contents of the first chamber into the second chamber causes the top of the chamber to pop up or expand to accommodate the contents of both chambers. The second chamber, that contains or is adjacent a piercing mechanism is then crushed by a plunger to dispense the mixed composition. The multi-chambered dosage form for mixing components prior to dispensing can be essentially doughnut shaped, with one or more chambers encircling or partially encircling a central chamber, or they may be positioned in a side by side arrangement or even stacked.
This present disclosure can also be described in certain embodiments as a dosage form for delivery of a pharmaceutical composition, in which the dosage form includes a first dosage chamber containing a first component of the pharmaceutical composition, a second dosage chamber containing a second component of the pharmaceutical composition, and a dispensing chamber that includes a piercable membrane. The second dosage chamber and the dispensing chamber may be two separate chambers, or the same chamber. The piercable membrane is a section of the membrane that is designed to be pierced by a piercing mechanism or device. The piercable membrane may include an area that is weakened by scoring, or thinned, effective to inhibit production of loose pieces of the membrane during use as it is penetrated, and to promote a seal of the pierced membrane to outer walls of the piercing tip. The dosage form also comprises a seal, for example first delamination seal, that prevents mixing of the contents of the first dosage chamber with the contents of the second dosage chamber, and may comprise a second delamination seal that prevents mixing of the contents of the second chamber with the dispensing chamber. The dosage form may further comprise a permanent seal, wherein the permanent seal surrounds the outer perimeter of all the chambers, and in which the first and second delamination seals have less adhesion than the permanent seal, such that the first and second delamination seals delaminate under significantly less pressure than the permanent seal.
As used herein, the term “dosage chamber”, which encompasses the term “dosage blister chamber”, refers to a compartment of the disclosed dosage forms that contain a component or a portion of the final pharmaceutical composition. A dosage chamber can contain a liquid or a solid composition, to be mixed with other components to form the final pharmaceutical composition when the contents of the chambers are combined during or just prior to administration. A “dispensing chamber”, which encompasses the term “dispensing blister chamber”, refers to a chamber that includes a piercable membrane and can include an internal piercing mechanism. Delamination zones are seals that are designed to break or delaminate when pressure is applied to the chambers so that the contents of the chambers can be mixed.
Certain dosage forms of the disclosure have two dosage chambers separated by a delamination zone, or in certain embodiments by a high vapor barrier material such as aluminum foil, for example. Embodiments also include dosage forms with three, four, five, or more dosage chambers, the contents of all of which are mixed as the pharmaceutical composition is delivered. The chambers can contain liquids or solids in any combination, however, in preferred embodiments, the final pharmaceutical composition is in liquid form. In certain embodiments one or more or even all of the dosage chambers can contain the same composition, or aliquots portions of the same composition when the volume of a dose is too large to fit within a single dosage chamber. It is an aspect of the disclosure that the dosage chambers are separated from each other during storage by delamination zones, or by membranes that can be pierced by a piercing device or burst by pressure, such that the barrier is removed when pressure is applied to the chambers in a delivery device, and that the final delamination or designed membrane failure is effective to allow the completed composition to enter the dispensing chamber for discharge to the site of treatment.
The present disclosure can also be described, therefore, as a method for dispensing a pharmaceutical composition comprising two components, wherein the two components are mixed in the dosage form immediately prior to dispensing. The method includes providing a multi chambered dosage form where a first component is contained in a first, crushable chamber and a second component is contained in a second, expandable chamber containing an internal piercing mechanism and a discharge outlet, where the first and second chamber are separated by an adhesive seal. The method further includes providing a mechanical pressure to crush the crushable chamber, breaking the adhesive seal and forcing the contents of the crushable chamber into the expandable chamber; and providing a second mechanical pressure to the expandable chamber to pierce the expandable chamber with the piercing mechanism and force the contents of the expandable chamber through the piercing mechanism and out the discharge outlet; where at least one of the components is a liquid. The method can also include first and second chambers arranged in a strip containing multiple sets of adjacent sealed chambers such that one chamber can be collapsed causing its contents to flow into the next chamber until the contents of all adjacent chambers of one set have been mixed in a single chamber of that set while the contents of all the remaining sets are kept separated. The strip can be fed into a dispensing device that includes a first stage compression wheel or plunger to collapse the adjacent chambers of the dosage form into the primary chamber and then transport that primary chamber to a position where the contents are dispensed by the second stage plunger while leaving the remaining sets of chambers in their original separated state. The method can further comprise a dosage form with three chambers, in which the contents of the first and second chambers are mixed in a third chamber that is pierced with either an internal or external piercing mechanism to dispense the dose.
It is a further aspect of the disclosure that any of the delivery devices or dosage forms described herein can include an indicator that the contents of the device has been exposed to extreme or potentially damaging high or low temperatures or to radiation levels that can cause the ingredients within the dosage forms to degrade or become inactive. A device can include, for example, irreversible temperature sensitive products such as strips, dots, decals, or labels containing crystalline materials that undergo an irreversible color change upon exposure to a particular temperature. Indicators can be used with various temperature sensitivities to create a visual history of temperature maxima and/or duration that the product has experienced. An example of such products are commercially marketed under the trade name, Thermax®, for example. Alternatively thermal sensitive ink can be used in the manufacture of the packaging for any of the devices or products disclosed herein, or such ink can be incorporated into or printed on the housing of a device or dosage form. Similar indicators can be used for the disclosed delivery devices and dosage forms to indicate radiation exposure. Typical indicators that detect high energy radiation change color from yellow to red upon exposure to radiation such as gamma rays. Other indicators can be used to detect exposure to ultraviolet or electron beam radiation. Certain of such labeled devices will find particular use in military applications or in extreme environments including deserts, tropical climates, extreme cold climates or even for use in space travel.
It is a further aspect of the disclosure that certain delivery devices can include a marking device such that a mark is produced on the user when a dosage is dispensed into the nostril of the user. Such a device is particularly useful in environments or situations such as pandemics, biological or chemical agent release or exposure events, or in institutions such as military, medical, educational or penal institutions in which a large number of subjects are required to receive an intranasal dose and it is important to be able to quickly determine who has received a dose. A preferred marking refill tip is a replaceable tip with dosage form for a nasal dispensing device similar to devices described in
Throughout this disclosure, unless the context dictates otherwise, the word “comprise” or variations such as “comprises” or “comprising,” is understood to mean “includes, but is not limited to” such that other elements that are not explicitly mentioned may also be included. Further, unless the context dictates otherwise, use of the term “a” or “the” may mean a singular object or element, or it may mean a plurality, or one or more of such objects or elements.
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
A preferred embodiment of an intranasal delivery device is shown in storage, ready and fired configurations in
The embodiment of an intranasal delivery device shown in
The nozzle end 32 designed for insertion into the nostril of a user, also provides an internal channel that contains the plunger 9, and a cavity designed to contain the dosage form 60 containing medication 62, and the external piercing mechanism 6. The piercing mechanism includes a piercing tip 8 and discharge channel 7 in fluid communication with the outlet 4.
The device is shown in the fired or dispensed mode in
Certain embodiments of the present disclosure are designed for use with an internally pierced blister 80. An example of such a device 90 is shown in
An alternative embodiment of device 90 is shown in
An alternative embodiment of an intranasal delivery device is shown in
An aspect of intranasal drug delivery devices as disclosed herein is delivery of the correct droplet size to the correct location. Droplets of 50 μm may be too large to penetrate the nasal cavities and droplets of less than 5 μm may pass directly into the lungs without being absorbed in the nasal mucosa. Up to 90% of the drug delivered using by conventional spray pumps is deposited in the anterior chamber of the nasal cavity then quickly cleared and swallowed. Doses are not consistent due to a poor user interface and variable spray characteristics. An aspect of the present disclosure is embodiments in which the device is correctly aligned for optimal delivery of drug to the nasal mucosa. For example, the device shown in
Another embodiment of an intranasal delivery device is shown in
An aspect of the present disclosure is the dosage forms to be used in the described delivery devices.
A top view and a section view at line A-A of an externally pierced dosage form 60 is shown in
An embodiment of a piercing nozzle 70 used to pierce the dosage form, control the flow of fluid and control the spray pattern and droplet size is illustrated in
Since the rate and method of absorption of various fluid medications are influenced by the droplet size and distribution inside the nasal cavity, it is beneficial to control this spray pattern. The surface features 74 can be designed for different types of spiral, vertical and other flow and the design can be adjusted for different viscosities of the fluid to be dispensed. For example, surface features may be added to create a vortex, to further mix the contents of the blister, to change the fluid property type from laminar to turbulent or vice versa or to change fluid properties such as pressure, velocity, surface tension or viscosity. This use of surface features to control spray pattern can also be applied to the discharge passage 55 of the piercing body 54 of the positive displacement dosage form 50 described earlier.
An embodiment of an internally pierced dosage form 80 containing a piercing nozzle 70 inside is illustrated in
Certain embodiments of the disclosure are designed to deliver a dose of medication in two increments, as a user might deliver one half dose to each nostril, for example. Such a device is termed a bi-dose device 100 as shown in
An embodiment of the present disclosure is re-usable device, an example of which is shown in
In certain embodiments, mixing of two separate compositions just before dispensing can be accomplished with the device shown in
As shown in
An embodiment of a push-button delivery device is shown in
The operation of the device can be better understood by referring to the cross sectional drawings,
Further features of the devices can be seen in
The device as shown in
With the device is in the ready position, the firing button is pressed until the second detents are overcome, and the button angled cam is forced down on the slide angled cam. Because of the interaction of the inclined planes, the slide is forced forward with a mechanical advantage relative to the force applied to the button, driving the plunger end 231 into the dosage form 222 with sufficient force to crush the dosage form and expel the liquid contents in the desired spray pattern (
An embodiment of a delivery device 300 for dispensing dual dosages is shown in the storage condition in
The operation of the device can be better understood by referring to the cross section drawings in
Sliding the activating tab 336 toward the first end of the body 310, as shown in
To dispense the second dose of medication, the activating tab 336 is moved in the reverse direction to the position shown in
An additional device for dispensing two medications or the same medication in two doses is shown in
An alternative to the previous device is shown in
There are occasions when it is desirable to introduce medication to both sides of the nose or nostrils. It may be preferred to introduce the medication or medications simultaneously or sequentially. Additionally, each nostril may receive the same medication, or a different medication may be delivered to each side.
A device for administration of two dosages in a side-by-side arrangement is shown in
A preferred embodiment of a marking tip assembly 600 is shown in cross-section in
All of the devices and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the devices and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the devices and/or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
This application is a divisional of U.S. Ser. No. 11/971,471, filed Jan. 9, 2008, and claiming benefit of priority of U.S. Provisional Application Ser. No. 60/853,328, filed Jan. 9, 2007, U.S. Provisional Application Ser. No. 60/944,700, filed Jun. 18, 2007, and U.S. Provisional Application Ser. No. 60/982,643, filed Oct. 25, 2007, the disclosures of all of which are incorporated into this application in their entirety by reference for all purposes. In addition, the disclosures of commonly owned U.S. Provisional Applications Ser. No. 60/938,379, filed May 16, 2007 and 60/978,619, filed Oct. 9, 2007 are also incorporated into this application in their entirety by reference for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1870558 | Darby | Aug 1932 | A |
| 2105946 | Lewis | Jan 1938 | A |
| 2307980 | Avrett | Jan 1943 | A |
| 2332799 | Hunn | Oct 1943 | A |
| 2442004 | Hayward-Butt | May 1948 | A |
| 2706984 | Lipari | Apr 1955 | A |
| 2885931 | McDonald | Apr 1955 | A |
| 3507277 | Altounyan et al. | Apr 1970 | A |
| 3512524 | Drewe | May 1970 | A |
| 3888263 | Watt et al. | Jun 1975 | A |
| 3949751 | Birch et al. | Apr 1976 | A |
| 3971377 | Damani | Jul 1976 | A |
| 4013075 | Cocozza | Mar 1977 | A |
| 4017007 | Riccio | Apr 1977 | A |
| 4090642 | Baker | May 1978 | A |
| 4095596 | Grayson | Jun 1978 | A |
| 4105027 | Lundquist | Aug 1978 | A |
| 4116195 | James | Sep 1978 | A |
| 4206758 | Hallworth et al. | Jun 1980 | A |
| 4423724 | Young | Jan 1984 | A |
| 4623337 | Maurice | Nov 1986 | A |
| 4627432 | Newell et al. | Dec 1986 | A |
| 4798288 | Holzner | Jan 1989 | A |
| 4952212 | Booth et al. | Aug 1990 | A |
| 4966581 | Landau | Oct 1990 | A |
| 5152284 | Valentini et al. | Oct 1992 | A |
| 5154710 | Williams | Oct 1992 | A |
| 5207217 | Cocozza et al. | May 1993 | A |
| 5215221 | Dirksing | Jun 1993 | A |
| 5219101 | Matkovich et al. | Jun 1993 | A |
| 5273190 | Lund | Dec 1993 | A |
| 5287850 | Haber et al. | Feb 1994 | A |
| 5307953 | Regan | May 1994 | A |
| 5327883 | Williams et al. | Jul 1994 | A |
| 5337740 | Armstrong et al. | Aug 1994 | A |
| 5379763 | Martin | Jan 1995 | A |
| 5411175 | Armstrong et al. | May 1995 | A |
| 5425480 | Rabenau et al. | Jun 1995 | A |
| 5431155 | Marelli | Jul 1995 | A |
| 5433343 | Meshberg | Jul 1995 | A |
| 5469989 | Graf et al. | Nov 1995 | A |
| 5492112 | Mecikalski et al. | Feb 1996 | A |
| 5497763 | Lloyd et al. | Mar 1996 | A |
| 5524419 | Shannon | Jun 1996 | A |
| 5529059 | Armstrong et al. | Jun 1996 | A |
| 5547131 | Brace | Aug 1996 | A |
| 5683361 | Elk et al. | Nov 1997 | A |
| 5715811 | Ohki et al. | Feb 1998 | A |
| 5769278 | Kummer et al. | Jun 1998 | A |
| 5810004 | Ohki et al. | Sep 1998 | A |
| 5881721 | Bunce et al. | Mar 1999 | A |
| 5896855 | Hobbs et al. | Apr 1999 | A |
| 5901703 | Ohki et al. | May 1999 | A |
| 5921236 | Ohki et al. | Jul 1999 | A |
| 5924417 | Braithwaite | Jul 1999 | A |
| 5944222 | Fuchs et al. | Aug 1999 | A |
| 5950619 | van der Linden et al. | Sep 1999 | A |
| 5964417 | Amann et al. | Oct 1999 | A |
| 5970974 | Van Der Linden et al. | Oct 1999 | A |
| 6101790 | Mori et al. | Aug 2000 | A |
| 6105761 | Peuker et al. | Aug 2000 | A |
| 6109479 | Ruckdeschel | Aug 2000 | A |
| 6116238 | Jackson et al. | Sep 2000 | A |
| 6123068 | Lloyd et al. | Sep 2000 | A |
| 6135755 | Zeiter et al. | Oct 2000 | A |
| 6138439 | McMahon et al. | Oct 2000 | A |
| RE37047 | Py | Feb 2001 | E |
| 6186141 | Pike et al. | Feb 2001 | B1 |
| 6321942 | Krampen et al. | Nov 2001 | B1 |
| 6367473 | Kafer | Apr 2002 | B1 |
| 6382465 | Greiner-Perth | May 2002 | B1 |
| 6425888 | Embleton et al. | Jul 2002 | B1 |
| 6443152 | Lockhart et al. | Sep 2002 | B1 |
| 6446839 | Ritsche | Sep 2002 | B1 |
| 6470650 | Lohwasser | Oct 2002 | B1 |
| 6484715 | Ritsche et al. | Nov 2002 | B1 |
| 6530371 | Jansen et al. | Mar 2003 | B2 |
| 6543448 | Smith et al. | Apr 2003 | B1 |
| 6644309 | Casper et al. | Nov 2003 | B2 |
| 6679248 | Stadelhofer | Jan 2004 | B2 |
| 6705313 | Niccolai | Mar 2004 | B2 |
| 6708846 | Fuchs et al. | Mar 2004 | B1 |
| 6725857 | Ritsche | Apr 2004 | B2 |
| 6726665 | Embleton et al. | Apr 2004 | B1 |
| 6730066 | Bennwik et al. | May 2004 | B1 |
| 6732732 | Edwards et al. | May 2004 | B2 |
| 6758837 | Peclat et al. | Jul 2004 | B2 |
| 6772915 | Helmlinger | Aug 2004 | B2 |
| 6782887 | Sullivan | Aug 2004 | B2 |
| 6877672 | Stihl | Apr 2005 | B2 |
| 6889690 | Crowder et al. | May 2005 | B2 |
| 6929005 | Sullivan et al. | Aug 2005 | B2 |
| 6957909 | Dingeldein et al. | Oct 2005 | B1 |
| 7097075 | Peuker et al. | Aug 2006 | B2 |
| 7143765 | Asking et al. | Dec 2006 | B2 |
| 7669597 | Sullivan et al. | Mar 2010 | B2 |
| 7963089 | Nelson et al. | Jun 2011 | B2 |
| 8047204 | Sullivan et al. | Nov 2011 | B2 |
| 20030199832 | Greiner-Perth et al. | Oct 2003 | A1 |
| 20040163645 | Connelly et al. | Aug 2004 | A1 |
| 20050000518 | Dunkley et al. | Jan 2005 | A1 |
| 20050016533 | Schuler et al. | Jan 2005 | A1 |
| 20050022813 | Alston | Feb 2005 | A1 |
| 20050048003 | Ohki et al. | Mar 2005 | A1 |
| 20050051166 | Glusker et al. | Mar 2005 | A1 |
| 20050056280 | Alston et al. | Mar 2005 | A1 |
| 20050081852 | Rangachari | Apr 2005 | A1 |
| 20050119605 | Sohn | Jun 2005 | A1 |
| 20050150492 | Dunkley et al. | Jul 2005 | A1 |
| 20050238708 | Jones et al. | Oct 2005 | A1 |
| 20060147389 | Staniforth et al. | Jul 2006 | A1 |
| 20060237009 | Jones et al. | Oct 2006 | A1 |
| 20070051362 | Sullivan | Mar 2007 | A1 |
| 20080123465 | Heusser et al. | May 2008 | A1 |
| 20080177246 | Sullivan et al. | Jul 2008 | A1 |
| 20080283439 | Sullivan et al. | Nov 2008 | A1 |
| 20100331765 | Sullivan et al. | Dec 2010 | A1 |
| 20110247305 | Nelson | Oct 2011 | A1 |
| 20110277763 | Sullivan et al. | Nov 2011 | A1 |
| Number | Date | Country |
|---|---|---|
| 1844809 | Oct 2007 | EP |
| 9125699 | Dec 1991 | GB |
| WO9420408 | Sep 1994 | WO |
| 9600050 | Jan 1996 | WO |
| 9723177 | Jul 1997 | WO |
| WO 2005032998 | Apr 2005 | WO |
| 2005102058 | Nov 2005 | WO |
| WO2005102058 | Nov 2005 | WO |
| WO2008086413 | Jul 2008 | WO |
| WO2008144439 | Nov 2008 | WO |
| WO2009036422 | Mar 2009 | WO |
| Entry |
|---|
| Abelson, M.B. and Rosner, Sarah A., “Prevent Drugs From Going Missing in Action,” Review of Opthalmology, Jun. 15, 2003, 10:6, pp. 96-98. |
| Abelson, M.B. and Shapiro, A., “Hitting the Bull's-eye With Drug Delivery,” Review of Opthalmology, Jul. 15, 2003, 10:7, pp. 82-84. |
| Aurora, Jack, “Nasal Delivery, Articles: Development of Nasal Delivery System: A review,” Drug Delivery Technology, 2002, 2(7); pp. 70-73. |
| Lofgren, Anders et al., “Blow-Fill-Seal Pharmaceutical Packaging—Towards Safe and Convenient Medical Containers” Business Briefing: Pharma Outsourcing, Jan. 2004, pp. 78-81. |
| Jenevieve B. Polin, “Blow-Fill-Seal Technology for Unit Dosing,” Pharmaceutical & Medical Packaging News, Sep. 2003. |
| O'Riordan, Thomas G., “Inhaled Antimicrobial Therapy: From Cystic Fibrosis to the Flu,” Respiratory Care, Jul. 2000, vol. 45, No. 7, pp. 836-845. |
| Saettone, Marco F “Progress and Problems in Opthalmic Drug Delivery,” Business Briefing: Pharmatech, May 2003, pp. 167-171. |
| Salt, Alec N., “Simulation of Methods for Drug Delivery to the Cochlear Fluids,” Felix D. Oestreicher, e. (eds.): Rational Pharmacotherapy of the Inner Ear. Adv. Otorhinolaryngol. Basel, Karger, 2002, vol. 59, p. 140. |
| Guidance for Industry, “Container Closure Systems for Packaging Human Drugs and Biologies,” U.S. Dept. of Health and Human Services, FDA, CDER, CBER, May 1999. |
| Guidance for Industry, “Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice,” U.S. Dept. of Health and Human Services. FDA, CDER, CBER, ORA, Sep. 2004. |
| Number | Date | Country | |
|---|---|---|---|
| 20130158474 A1 | Jun 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60853328 | Jan 2007 | US | |
| 60944700 | Jun 2007 | US | |
| 60982643 | Oct 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11971471 | Jan 2008 | US |
| Child | 13770861 | US |
